Skip to content

Effect of quyushengxin recipe on intestinal microorganism in patients with ulcerative colitis

Based on intestinal macrovirus histology studying the mechanism of Quyushengxin to regulate ulcerative colitis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900023349
Enrollment
Unknown
Registered
2019-05-23
Start date
2017-06-05
Completion date
Unknown
Last updated
2019-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of T.C.M
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria for normal volunteers: 1) normal healthy without any previous medical history; 2) the defecation law is unobstructed and the fecal material is soft forming; 3) persons aged between 18 and 65 years; 4) good compliance with researchers' observation, voluntary participation, and signing of informed consent. Ulcerative colitis group inclusion criteria: 1) those with clinical symptoms, colonoscopy and intestinal mucosa biopsy pathological specimens meeting the diagnostic criteria at the same time; 2) persons aged between 18 and 65 years; 3) the activity score of ulcerative colitis evaluated by the modified Mayo scoring system is less than or equal to 10 points; 4) good compliance with researchers' observation, voluntary participation, and signing of informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria for normal volunteers: 1) those who do not meet the inclusion criteria; 2) pregnant or lactating women with allergies. Ulcerative colitis group exclusion criteria: 1) clinical symptoms, colonoscopy findings, or pathological specimens of intestinal mucosa biopsy fail to meet the diagnostic criteria; 2) pregnant or lactating women, allergic constitution and allergic to the observed drugs; 3) patients with severe primary diseases of cardiovascular, cerebrovascular, liver, kidney and hematopoietic system; 4) patients with intestinal stenosis, intestinal obstruction, intestinal perforation, rectal polyps, toxic colonic dilatation, colon cancer, rectal cancer and anal diseases;Acute fulminant, severe patients; 5) the patient fails to use the medicine as prescribed, and the efficacy cannot be judged or the efficacy is affected by incomplete data.

Design outcomes

Primary

MeasureTime frame
Enteric Virome;intestinal flora;DAI;

Countries

China

Contacts

Public ContactZhenyi Wang

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of T.C.M

drxinhuo@163.com+86 13601760317

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026